

1647

Please Direct All Correspondence to Customer Number 30,313



TRANSMITTAL LETTER
INFORMATION DISCLOSURE STATEMENT

Applicant : Audrey GODDARD et al.

App. No : 10/063,602

Filed : May 3, 2002

For : SECRETED AND TRANSMEMBRANE
POLYPEPTIDES AND NUCLEIC ACIDS
ENCODING THE SAME

Examiner : WEGERT, Sandra L.

Art Unit : 1647

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 11, 2006

(Date)

AnneMarie Kaiser, Reg. No. 37,649

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Enclosed for filing in the above-identified application are:

(X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:


- (X) Listing 16 references.
- (X) Enclosing 16 references.

(X) Return prepaid postcard.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.



AnneMarie Kaiser
Registration No. 37,649
Attorney of Record
Customer No. 30,313
(619) 235-8550



INFORMATION DISCLOSURE STATEMENT


Applicant : Audrey GODDARD et al.
 App. No : 10/063,602
 Filed : May 3, 2002
 For : SECRETED AND
 TRANSMEMBRANE POLYPEPTIDES
 AND NUCLEIC ACIDS ENCODING
 THE SAME
 Examiner : WEGERT, Sandra L.
 Art Unit : 1647

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 11, 2006

(Date)


AnneMarie Kaiser, Reg. No. 37,649

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 16 references to be considered by the Examiner. Also enclosed are 16 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed within three months of the filing date, with an RCE or before receipt of a first office action after an RCE and no fee is required.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated:

Sept. 11, 2006

By:


AnneMarie Kaiser
Registration No. 37,649
Attorney of Record
Customer No. 30,313
(619) 235-8550



INFORMATION DISCLOSURE STATEMENT BY APPLICANT	
(Multiple sheets used when necessary)	
SHEET 1 OF 2	

Application No.	10/063,602
Filing Date	May 3, 2002
First Named Inventor	Goddard, et al.
Art Unit	1647
Examiner	WEGERT, Sandra L.
Attorney Docket No.	GNE.3230R1C74

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	1	Berner, et al., "Clinicopathological association of CD44 mRNA and protein expression expression in primary breast carcinomas" <i>Histopathology</i> (2003) 42:546-554.			
	2	Brooks, et al., "cDNA array identification of genes regulated in rat renal medulla in response to vasopressin infusion" <i>Am J Physiol</i> (2003) 284:F218-F228.			
	3	Conrads, et al., "A Combined Proteome and Microarray Investigation of Inorganic Phosphate-induced Pre-osteoblast Cells" <i>Mol. Cell Proteomics</i> , 4(9):1284-1296 (2005).			
	4	Czupalla, et al., "Comparative study of protein and mRNA expression during osteoclastogenesis" <i>Proteomics</i> 5:3868-3875 (2005).			
	5	Ginestier, et al. 2002. "Distinct and Complementary Information Provided by Use of Tissue and DNA Microarrays in the Study of Breast Tumor Markers" <i>Am. J. Pathol.</i> , 161:1223-1233.			
	6	Gronborg, et al. "Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach," <i>Mol Cell Proteomics</i> . 2006, Jan;5(1):157-71. Epub 2005 Oct 8. (ABSTRACT ONLY)			
	7	Kawamoto et al., "Expression Profiles of Active Genes in Human and Mouse Livers," <i>Gene</i> , 1996 Sep 26;174(1):151-8.			
	8	KING, et al. 2001. "Gene Expression Profile Analysis by DNA Microarrays" <i>JAMA</i> , 286(18):2280-2288.			
	9	Kwong, et al., "Synchronous global assessment of gene and protein expression in colorectal cancer progression" <i>Genomics</i> , 86:142-158 (2005).			
	10	LEDERMAN, et al. 1991. "A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4." <i>Molecular Immunology</i> , 28(11):1171-1181.			
	11	LEE, et al. "Importance of replication in microarray gene expression studies: Statistical methods and evidence from repetitive cDNA hybridizations" <i>Proc. Natl. Acad. USA</i> , 97(18):9834-9839			
	12	Oda, et al., "Expression of MDR1/p-glycoprotein and multidrug resistance-associated protein in childhood solid tumors" <i>Virchows Arch</i> (1997) 430:99-105			
	13	Sugg, et al., "Cytoplasmic staining of erbB-2 but not mRNA levels correlates with differentiation in human thyroid neoplasia" <i>Clinical Endocrinology</i> (1998) 49:629-637.			
	14	Toler, et al., "Loss of communication in ovarian cancer" <i>American Journal of Obstetrics and Gynecology</i> , (2006) 194:e27-e31.			

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

^{T¹} - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/063,602
		Filing Date	May 3, 2002
		First Named Inventor	Goddard, et al.
		Art Unit	1647
<i>(Multiple sheets used when necessary)</i>		Examiner	WEGERT, Sandra L.
SHEET 2 OF 2		Attorney Docket No.	GNE.3230R1C74

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	15	Washburn, et al., "Protein pathway and complex clustering of correlated mRNA and protein expression analyses in <i>Saccharomyces cerevisiae</i> " <i>Proc. Natl. Acad. Sci.</i> 100(6): 3107-3112. (2003)	
	16	WILDSMITH, et al. "Gene Expression Analysis Using Microarrays" <i>Molecular Biology in Cellular Pathology</i> Ed. John Crocker and Paul G. Murray, pages 269-286.	

2863770/082306

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.